Govindaswami Ragupathi

Govindaswami Ragupathi serves as an Attending Physician and Physician Scientist at Memorial Sloan Kettering Cancer Center (MSK), affiliated with the Department of Medicine, Solid Tumor Oncology Division, and Melanoma and Immunotherapeutics Service. He is an active member of the Melanoma Disease Management Team, contributing to clinical and translational oncology research.

His research focuses on cancer vaccine development and immunotherapeutic strategies, particularly for melanoma and neuroblastoma. Key interests include ganglioside-based vaccines, microbiome-vaccine interactions, and adjuvant therapies like β-glucan to enhance immune responses in high-risk pediatric cancers. His work bridges surgical oncology and immunology, emphasizing clinical translation.

Ragupathi's recent publications reveal a dual focus: surgical innovation (2025 JAMA Surgery study on minimally invasive techniques) and cancer immunotherapeutics (2023 JAMA Oncology phase 2 trial of ganglioside vaccines with β-glucan for neuroblastoma). These reflect his commitment to improving outcomes through both technical refinement and immune modulation.

With 90 journal articles, 50 meeting abstracts, and 5 book sections, he maintains a prolific scholarly output. His 53 MSK co-authorships—including collaborations with Livingston, Danishefsky, and Slovin—highlight extensive institutional partnerships. Ragupathi actively contributes to MSK's research ecosystem through the Melanoma Disease Management Team and Solid Tumor Oncology Division.